Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1

Journal of Virology

Volumn 85, Issue 6, 2011, Pages 2524-2535

  Changela, Anita ^a   Wu, Xueling ^a   Yang, Yongping ^a   Zhang, Baoshan ^a   Zhu, Jiang ^a   Nardone, Glenn A ^a   O'Dell, Sijy ^a   Pancera, Marie ^a   Gorny, Miroslaw K ^b   Phogat, Sanjay ^c   Robinson, James E ^d   Stamatatos, Leonidas ^e,f   Zolla Pazner, Susan ^b,g   Mascola, John R ^a   Kwong, Peter D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Seattle BioMed   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2909; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY STRUCTURE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; GENETIC VARIABILITY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CRYSTALLOGRAPHY, X-RAY; HIV ANTIBODIES; HIV-1; HUMANS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952396269     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02335-10     Document Type: Article

References (49)

1. Adams, P. D., et al. 2004. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Synchrotron Radiat. 11:53-55. (Pubitemid 40085633)
2. Allcorn, L. C., and A. C. Martin. 2002. SACS - self-maintaining database of antibody crystal structure information. Bioinformatics 18:175-181.
3. Barouch, D. H., et al. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79:8828-8834. (Pubitemid 40934793)
4. Burke, V., et al. 2009. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 17:1538-1546.
5. Chang, W. C., et al. 2009. Incorporating support vector machine for identifying protein tyrosine sulfation sites. J. Comput. Chem. 30:2526-2537.
6. Chen, C. H., L. Jin, C. Zhu, S. Holz-Smith, and T. J. Matthews. 2001. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate. J. Virol. 75:6700-6704.
7. Chen, L., et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127.
8. Chen, V. B., et al. 2010. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66:12-21.
9. Cho, M. W., M. K. Lee, C. H. Chen, T. Matthews, and M. A. Martin. 2000. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate. J. Virol. 74:9749-9754.
10. Collaborative Computational Project, No. 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
11. DeLano, W. L. 2002. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA.
12. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
13. Etemad-Moghadam, B., et al. 1998. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys. J. Virol. 72:8437-8445. (Pubitemid 28421853)
14. Gorny, M. K., et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237. (Pubitemid 40464273)
15. Holm, L., and C. Sander. 1995. Dali: a network tool for protein structure comparison. Trends Biochem. Sci. 20:478-480.
16. Honnen, W. J., et al. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81:1424-1432. (Pubitemid 46167863)
17. Huang, C. C., et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
18. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47(Pt. 2):110-119.
19. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of proteins of immunological interest, 5th ed. U.S. Department of Health and Human Service, National Institutes of Health, Bethesda, MD.
20. Kimura, T., X. H. Wang, C. Williams, S. Zolla-Pazner, and M. K. Gorny. 2009. Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. Hum. Antibodies 18:35-40.
21. Kraft, Z., et al. 2007. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J. Virol. 81:6402-6411. (Pubitemid 46878046)
22. Kwong, P. D., et al. 1999. Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J. Biol. Chem. 274:4115-4123.
23. Kwong, P. D., et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659. (Pubitemid 28289647)
24. Larkin, M. A., et al. 2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. (Pubitemid 350162903)
25. Leitner, T. F., et al. 2006. HIV Sequence Compendium 2005. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
26. McCoy, A. J., et al. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40:658-674.
27. Monigatti, F., E. Gasteiger, A. Bairoch, and E. Jung. 2002. The Sulfinator: predicting tyrosine sulfation sites in protein sequences. Bioinformatics 18:769-770. (Pubitemid 34679127)
28. Moore, K. L. 2003. The biology and enzymology of protein tyrosine Osulfation. J. Biol. Chem. 278:24243-24246.
29. Morris, L., et al. 2010. How does neutralization breadth develop in HIV infection?, abstr. 013, p. 65. 2010 Keystone HIV Vaccine Symp., Banff, Canada.
30. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. (Pubitemid 27085611)
31. Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
32. Pejchal, J., L. M. Walker, D. R. Burton, and I. A. Wilson. 2010. Characterization of heterogeneity in PG9 tyrosine sulfation. AIDS Res. Hum. Retrovir. 26:A155-A156.
33. Pejchal, R., et al. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
34. Petrey, D., et al. 2003. Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins 53(Suppl. 6):430-435. (Pubitemid 37352202)
35. Popkov, M., et al. 2003. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J. Mol. Biol. 325:325-335.
36. Robinson, J. E., et al. 2010. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J. Virol. 84:3443-3453.
37. Seaman, M. S., et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
38. Smith, K., et al. 2009. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4:372-384.
39. Stanfield, R. L., M. K. Gorny, C. Williams, S. Zolla-Pazner, and I. A. Wilson. 2004. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 12:193-204.
40. Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
41. Walker, L. M., et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
42. Wang, G., and R. L. Dunbrack, Jr. 2003. PISCES: a protein sequence culling server. Bioinformatics 19:1589-1591.
43. Wu, X., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
44. Wu, X., et al. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 83:10892-10907.
45. Zhang, Y., and J. Skolnick. 2005. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 33:2302-2309. (Pubitemid 41439897)
46. Zhou, H., and Y. Zhou. 2002. Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction. Protein Sci. 11:2714-2726. (Pubitemid 35191145)
47. Zhou, T., et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
48. Zhou, T., et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737. (Pubitemid 46279718)
49. Zolla-Pazner, S., and T. Cardozo. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10:527-535.